By continuing, you agree to the Terms of Service.
This website uses cookies to enhance your browsing experience. Learn More.
Essential Cookies
Optional Cookies
Login
Logo for company Hangzhou Tigermed Consulting Co., Ltd.

Hangzhou Tigermed Consulting Co., Ltd. (300347.SZ)

SHZ Currency in CNY
¥63.51
-¥0.23
-0.36%
Last Update: 29 Aug 2025, 07:04
¥46.86B
Market Cap
56.20
P/E Ratio (TTM)
0.47%
Forward Dividend Yield
¥41.61 - ¥82.79
52 Week Range

300347.SZ Stock Price Chart

Explore Hangzhou Tigermed Consulting Co., Ltd. interactive price chart. Choose custom timeframes to analyze 300347.SZ price movements and trends.

300347.SZ Company Profile

Discover essential business fundamentals and corporate details for Hangzhou Tigermed Consulting Co., Ltd. (300347.SZ) to support your stock research and investment decisions.

Sector

Healthcare

Industry

Medical - Diagnostics & Research

IPO Date

17 Aug 2012

Employees

10.19K

CEO

Xiaoping Ye D.Phil, EMBA,

Description

Hangzhou Tigermed Consulting Co., Ltd. provides contract research organization services in the People's Republic of China and internationally. It operates in Clinical Trial Solutions, and Clinical-related and Laboratory Services segments. The company offers regulatory submission and approval, medical translation, and good manufacturing practice (GMP) consulting services; and clinical services in the areas of medical science, early clinical and late phase development, medical monitoring, project management, patient recruitment, and quality management system. It also provides biometrics services comprising data management, biostatistics, and statistical programming; and integrated technology services, such as site management, pharmacovigilance, third party audit and training, medical imaging, clinical trial system solution, central laboratory, pre-clinical, and research hospital. Further, the company offers medical device/ in vitro diagnostics (IVD) services comprising medical device testing, regulatory submission, clinical evaluation and trials, GMP certificate, EU MDR and IVDR preparation, and value-added services; and post-marketing study, real world evidence, and vaccine clinical trial services. Hangzhou Tigermed Consulting Co., Ltd. was incorporated in 2004 and is headquartered in Hangzhou, the People's Republic of China.

300347.SZ Financial Timeline

Browse a chronological timeline of Hangzhou Tigermed Consulting Co., Ltd. corporate events including earnings releases, dividend announcements, and stock splits.

Upcoming earnings on 28 Apr 2026

Upcoming earnings on 27 Mar 2026

Upcoming earnings on 29 Oct 2025

Earnings released on 28 Aug 2025

EPS came in at ¥0.25 falling short of the estimated ¥0.35 by -28.51%, while revenue for the quarter reached ¥1.69B , missing expectations by -5.68%.

Dividend declared on 17 Jun 2025

A dividend of ¥0.30 per share was announced, adjusted to ¥0.30. The dividend was paid on 17 Jun 2025.

Earnings released on 28 Apr 2025

EPS came in at ¥0.19 falling short of the estimated ¥0.27 by -29.63%, while revenue for the quarter reached ¥1.56B , missing expectations by -15.66%.

Earnings released on 26 Mar 2025

EPS came in at -¥0.47 falling short of the estimated ¥0.55 by -185.45%, while revenue for the quarter reached ¥1.54B , missing expectations by -9.24%.

Earnings released on 29 Oct 2024

EPS came in at ¥0.37 falling short of the estimated ¥0.54 by -31.48%, while revenue for the quarter reached ¥1.71B , missing expectations by -13.94%.

Earnings released on 28 Aug 2024

EPS came in at ¥0.30 falling short of the estimated ¥0.50 by -40.00%, while revenue for the quarter reached ¥1.69B , missing expectations by -17.19%.

Dividend declared on 12 Jul 2024

A dividend of ¥0.57 per share was announced, adjusted to ¥0.57. The dividend was paid on 12 Jul 2024.

Earnings released on 25 Apr 2024

EPS came in at ¥0.27 falling short of the estimated ¥0.53 by -49.06%, while revenue for the quarter reached ¥1.65B , missing expectations by -17.28%.

Earnings released on 28 Mar 2024

EPS came in at ¥0.17 falling short of the estimated ¥0.46 by -63.04%, while revenue for the quarter reached ¥1.73B , missing expectations by -11.54%.

Earnings released on 27 Oct 2023

EPS came in at ¥0.57 falling short of the estimated ¥0.75 by -24.00%, while revenue for the quarter reached ¥1.94B , missing expectations by -4.23%.

Earnings released on 25 Aug 2023

EPS came in at ¥0.95 surpassing the estimated ¥0.65 by +46.15%, while revenue for the quarter reached ¥1.91B , missing expectations by -13.14%.

Dividend declared on 7 Jul 2023

A dividend of ¥0.55 per share was announced, adjusted to ¥0.55. The dividend was paid on 7 Jul 2023.

Earnings released on 25 Apr 2023

EPS came in at ¥0.66 surpassing the estimated ¥0.61 by +8.20%, while revenue for the quarter reached ¥1.80B , missing expectations by -23.18%.

Earnings released on 28 Mar 2023

EPS came in at ¥0.46 falling short of the estimated ¥0.62 by -25.81%, while revenue for the quarter reached ¥1.68B , beating expectations by +8.42%.

Earnings released on 25 Oct 2022

EPS came in at ¥0.48 falling short of the estimated ¥0.66 by -27.27%, while revenue for the quarter reached ¥1.81B , beating expectations by +7.57%.

Earnings released on 25 Aug 2022

EPS came in at ¥0.78 surpassing the estimated ¥0.64 by +21.88%, while revenue for the quarter reached ¥1.78B , beating expectations by +36.08%.

Dividend declared on 31 May 2022

A dividend of ¥0.50 per share was announced, adjusted to ¥0.50. The dividend was paid on 31 May 2022.

Earnings released on 26 Apr 2022

EPS came in at ¥0.60 falling short of the estimated ¥0.63 by -4.76%, while revenue for the quarter reached ¥1.82B , beating expectations by +28.38%.

Earnings released on 11 Mar 2022

EPS came in at ¥1.27 surpassing the estimated ¥0.45 by +182.22%, while revenue for the quarter reached ¥1.82B , beating expectations by +21.23%.

Earnings released on 22 Oct 2021

EPS came in at ¥0.61 surpassing the estimated ¥0.41 by +48.78%, while revenue for the quarter reached ¥1.34B .

Earnings released on 26 Aug 2021

EPS came in at ¥0.92 surpassing the estimated ¥0.54 by +70.37%, while revenue for the quarter reached ¥1.15B .

Dividend declared on 1 Jun 2021

A dividend of ¥0.30 per share was announced, adjusted to ¥0.30. The dividend was paid on 1 Jun 2021.

Earnings released on 28 Apr 2021

EPS came in at ¥0.52 surpassing the estimated ¥0.39 by +33.33%, while revenue for the quarter reached ¥901.95M .

Earnings released on 29 Mar 2021

EPS came in at ¥0.49 surpassing the estimated ¥0.18 by +172.22%, while revenue for the quarter reached ¥891.81M .

Earnings released on 30 Oct 2020

EPS came in at ¥0.39 surpassing the estimated ¥0.35 by +11.43%, while revenue for the quarter reached ¥848.47M .

300347.SZ Stock Performance

Access detailed 300347.SZ performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.

Explore Related Stocks

Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.

Discover More
Command Palette
Search for a command to run